Poultry Vaccines Market to grow at a CAGR of 9.55% during 2026 to 2035; Driven by Rising Prevalence of Poultry Diseases and Increasing Focus on Livestock Health

Market Highlights

The Poultry Vaccines Market was valued at USD 2.45 billion in 2025 and is projected to reach USD 2.66 billion by 2026 before climbing to USD 6.05 billion by 2035, expanding at a 9.55% CAGR during the 2026–2035 forecast window.

The market growth is primarily driven by rising global poultry consumption, increasing disease outbreaks, and technological advancements in vaccine development. The demand for safe, effective, and sustainable poultry vaccines is expanding as poultry products remain a key source of affordable protein worldwide. Governments and private enterprises are also emphasizing preventive health programs to mitigate the economic losses caused by avian diseases, thereby strengthening vaccine adoption across regions.

Emerging vaccine technologies — such as recombinant, DNA, and vector-based vaccines — are revolutionizing the market by improving disease prevention, reducing antibiotic reliance, and aligning with One Health and biosecurity initiatives. The ongoing shift toward digital farm management and precision livestock monitoring further supports efficient vaccination programs and enhanced poultry productivity.

MRFR recognizes the following companies as the key players in the Global Poultry Vaccines Market: Bioniche Animal Health, Vetoquinol, Elanco, Ceva Santé Animale, Indian Immunologicals, Merck Animal Health, Phibro Animal Health, MVP Labs, AgriLabs, Boehringer Ingelheim, Valley Veterinary, Merial, Zoetis, and HIPRA.

Segment Analysis

The Global Poultry Vaccines Market has been segmented based on Type, Species, Administration Route, Disease Targeted, and Region.

By Type, the market has been segmented into Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, and DNA Vaccines. Among these, the Live Attenuated Vaccines segment dominated the market, valued at USD 1.6 Billion in 2024, and is projected to reach USD 2.5 Billion by 2035. These vaccines are widely adopted due to their strong immune response and cost efficiency. Inactivated Vaccines are expected to follow, reaching USD 2.2 Billion by 2035, favored for their safety and disease-specific protection.

Based on species, the market includes Broilers, Layers, Turkeys, and Others. The Broilers segment accounted for the largest share in 2024, driven by the surge in global meat demand and the need to prevent high-mortality diseases. Layers are expected to grow significantly due to increasing egg consumption and enhanced biosecurity measures in poultry farms.

Administration Route include Intramuscular, Subcutaneous, Oral, and Inhalation. Among these, the Intramuscular segment dominates the market due to its high efficacy and quick immune response. Meanwhile, Oral vaccines are gaining traction for their ease of administration and stress-free delivery in large-scale operations.

Based on disease type, the market covers Newcastle Disease, Infectious Bursal Disease, Avian Influenza, and Marek’s Disease. The Newcastle Disease segment leads the market due to its high global prevalence, followed by Avian Influenza, which continues to pose a major zoonotic risk, prompting extensive vaccination campaigns.

Regional Insights

The Asia Pacific Poultry Vaccines Market is anticipated to hold the largest market share by 2035, driven by expanding poultry production and growing awareness of disease control. North America follows closely, with a well-established poultry sector and strong R&D investment by companies like Zoetis and Merck Animal Health. Meanwhile, Europe is focusing on sustainable poultry production and biosecurity measures, whereas Latin America and the Middle East & Africa regions are witnessing rising vaccination initiatives to combat endemic poultry diseases.

Key Findings of the Study

• Breeder-flock immunization generated USD 1.16 billion in 2025, anchoring parental immunity transfer strategies across vertically integrated operations.


• Layer-flock programs are on track for a 9.7% CAGR as egg production scales in South and Southeast Asia.


• North America accounted for 34% of total Poultry Vaccines Market revenue in 2025, driven by USDA-regulated broiler complexes.


• Asia-Pacific is set to grow at an 11.2% CAGR through 2035 as China and India expand commercial poultry infrastructure.